Plasma cell neoplasm

Researchers are testing a combination of three drugs, belantamab mafodotin, cevostamab, and pomalidomide, in adults whose multiple myeloma has returned after at least two prior treatments. The phase 1b trial aims to find the best dose and see how well the combination controls the…

This phase 2 trial is testing an investigational drug called QLS4131 in people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up in organs and cause damage. QLS4131 is a trispecific antibody designed to target and eliminate the plasma cells produci…

This study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …

This early-phase study tests the safety of a new immunotherapy that creates cancer-fighting cells inside the body for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The treatment targets two proteins (BCMA and GPRC5D) on cancer cells. Researcher…

This Phase 2 trial tests a new drug called QLS4131, given under the skin, in combination with other medications for people with malignant plasma cell neoplasms like multiple myeloma. The study will compare different drug combinations to see which works best at shrinking tumors an…

This early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…

This early-phase trial tests a new type of immune cell therapy called GPRC5D CAR-T in 18 people with relapsed or treatment-resistant plasma cell disorders, such as multiple myeloma. The therapy involves giving patients a single infusion of their own modified immune cells designed…

This study tests a new radioactive tracer for PET/CT scans that targets a protein called GPRC5D found on multiple myeloma cells. About 50 adults with plasma cell disorders, including multiple myeloma, will receive the tracer and then undergo imaging. The goal is to see if this me…

This study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…

This study aims to enroll 10,000 adults across the United States to help identify genetic variants linked to blood cancers such as leukemia, lymphoma, and myeloma. Participants complete online health surveys and provide a saliva sample by mail. Researchers will analyze the DNA to…

This study will check if old tissue samples from 15 patients with extramedullary multiple myeloma can be used to find new biomarkers. Researchers will look at the samples and medical records to see if they are good enough for future research. No new treatments or tests are given—…

This study follows 65 patients getting stem cell transplants for blood cancers to see how their immune systems rebuild. Researchers will track B cells and antibody responses to vaccines before and after transplant. The goal is to improve vaccination schedules and infection protec…